c-src homology 3 domains (SH3) modulate the formation of a number of protein complexes that are important in cell signaling and cytoskeletal organization. The SH3 domain is recognized by short conserved proline-rich motifs which adopt left-handed polyproline helices on binding. In order to examine m
Src homology-2 domain binding assays by scintillation proximity and surface plasmon resonance
✍ Scribed by Eliane Mandine; Dominique Gofflo; Véronique Jean-Baptiste; Edoardo Sarubbi; Gaetan Touyer; Pierre Deprez; Dominique Lesuisse
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- English
- Weight
- 124 KB
- Volume
- 14
- Category
- Article
- ISSN
- 0952-3499
- DOI
- 10.1002/jmr.542
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Various SH2 competitive binding assays, based on different techniques, have been described in the literature to identify and characterize SH2 ligands. The consideration that most reported methods show experimental limitations associated with assay parameters has prompted us to base our Src‐SH2 inhibitor discovery program on the use of two different assays.
In this study, two conceptually different biochemical methods designed to discover Src‐SH2 inhibitors, respectively scintillation proximity assay (SPA) and surface plasmon resonance (SPR), have been evaluated and compared. For its high sensitivity and adaptability to automation SPA was chosen for high capacity screening (primary screen), whereas SPR was used for hits confirmation (secondary screening). However with the drastic improvement of inhibitor affinities, the limit of sensitivity was rapidly reached for the SPR assay based on the canonical pYEEI ligand. The substitution of the natural, monophosphorylated peptide ligand with a triphosphorylated peptide has allowed us to remarkably increase its sensitivity, so that molecules with nanomolar affinities could be easily differentiated in terms of IC~50~ ranking. Such a new, improved SPR assay can be of great interest for the study of high affinity ligands of different SH2‐based drug targets. Copyright © 2001 John Wiley & Sons, Ltd.
📜 SIMILAR VOLUMES
## Abstract CD 19 is a B cell surface protein capable of forming non‐covalent molecular complexes with a number of other B cell surface proteins including the CD21/CD81/Leu‐13 complex as well as with surface immunoglobulin. CD19 tyrosine phosphorylation increases after B cell activation, and is pro
We explored the use of a newly developed cuvettebased surface plasmon resonance (SPR) instrument (IBIS) to study peptide-protein interactions. We studied the interaction between the SH2 domain of lck and a phosphotyrosine peptide EPQY\*EEIPIYL which was immobilized on a sensor chip. No indications f